Brokers Set Expectations for Atyr PHARMA FY2024 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Atyr PHARMA in a report released on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($0.89) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Atyr PHARMA’s Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $0.16 EPS, FY2028 earnings at $1.29 EPS and FY2029 earnings at $1.82 EPS.

Several other equities research analysts have also commented on the company. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Cantor Fitzgerald began coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They issued an “overweight” rating on the stock. Finally, Leerink Partners started coverage on shares of Atyr PHARMA in a research note on Tuesday. They set an “outperform” rating and a $16.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Trading Up 12.1 %

Shares of ATYR opened at $4.25 on Thursday. Atyr PHARMA has a twelve month low of $1.42 and a twelve month high of $4.29. The firm has a market capitalization of $356.75 million, a P/E ratio of -4.52 and a beta of 1.10. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $3.56 and its 200 day simple moving average is $2.85.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ATYR. Alpine Global Management LLC purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $63,000. Woodline Partners LP acquired a new stake in shares of Atyr PHARMA during the fourth quarter worth approximately $6,092,000. Squarepoint Ops LLC bought a new stake in shares of Atyr PHARMA in the fourth quarter worth $96,000. Two Sigma Advisers LP acquired a new stake in Atyr PHARMA in the fourth quarter valued at $44,000. Finally, Two Sigma Investments LP bought a new position in Atyr PHARMA during the 4th quarter valued at $78,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.